Trial NCT04864561
Publication Lazarus R, Lancet Infect Dis, 2022
Primary outcome on the report: 1) Geometric mean titre (GMT) ratio and seroconversion of SARS-CoV-2-specific nAbs on day 43 ; 2) Frequency and severity of any adverse events up to day 43 after baseline in all participants.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.